Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Kosiuk, Jedrzej (55237676500)"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Current perspectives on wearable rhythm recordings for clinical decision-making: The wEHRAbles 2 survey
    (2021)
    Manninger, Martin (55415666300)
    ;
    Zweiker, David (56411942100)
    ;
    Svennberg, Emma (55531584500)
    ;
    Chatzikyriakou, Sofia (18834372300)
    ;
    Pavlovic, Nikola (23486720000)
    ;
    Zaman, Junaid A.B. (56377827600)
    ;
    Kircanski, Bratislav (55351539500)
    ;
    Lenarczyk, Radoslaw (6603516741)
    ;
    Vanduynhoven, Philippe (56112526600)
    ;
    Kosiuk, Jedrzej (55237676500)
    ;
    Potpara, Tatjana (57216792589)
    ;
    Duncker, David (36090817400)
    Novel wearable devices for heart rhythm analysis using either photoplethysmography (PPG) or electrocardiogram (ECG) are in daily clinical practice. This survey aimed to assess impact of these technologies on physicians' clinical decision-making and to define, how data from these devices should be presented and integrated into clinical practice. The online survey included 22 questions, focusing on the diagnosis of atrial fibrillation (AF) based on wearable rhythm device recordings, suitable indications for wearable rhythm devices, data presentation and processing, reimbursement, and future perspectives. A total of 539 respondents {median age 38 [interquartile range (IQR) 34-46] years, 29% female} from 51 countries world-wide completed the survey. Whilst most respondents would diagnose AF (83%), fewer would initiate oral anticoagulation therapy based on a single-lead ECG tracing. Significantly fewer still (27%) would make the diagnosis based on PPG-based tracing. Wearable ECG technology is acceptable for the majority of respondents for screening, diagnostics, monitoring, and follow-up of arrhythmia patients, while respondents were more reluctant to use PPG technology for these indications. Most respondents (74%) would advocate systematic screening for AF using wearable rhythm devices, starting at patients' median age of 60 (IQR 50-65) years. Thirty-six percent of respondents stated that there is no reimbursement for diagnostics involving wearable rhythm devices in their countries. Most respondents (56.4%) believe that costs of wearable rhythm devices should be shared between patients and insurances. Wearable single- or multiple-lead ECG technology is accepted for multiple indications in current clinical practice and triggers AF diagnosis and treatment. The unmet needs that call for action are reimbursement plans and integration of wearable rhythm device data into patient's files and hospital information systems. © 2021 Published on behalf of the European Society of Cardiology. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)
    (2023)
    Savelieva, Irina (6701768664)
    ;
    Fumagalli, Stefano (57190111211)
    ;
    Kenny, Rose Anne (57640746800)
    ;
    Anker, Stefan (56223993400)
    ;
    Benetos, Athanase (56844949800)
    ;
    Boriani, Giuseppe (57675336900)
    ;
    Bunch, Jared (59158207400)
    ;
    Dagres, Nikolaos (7003639393)
    ;
    Dubner, Sergio (55964804300)
    ;
    Fauchier, Laurent (7005282545)
    ;
    Ferrucci, Luigi (57215726620)
    ;
    Israel, Carsten (7005881304)
    ;
    Kamel, Hooman (35085093700)
    ;
    Lane, Deirdre A. (57203229915)
    ;
    Lip, Gregory Y.H. (57216675273)
    ;
    Marchionni, Niccolò (7006174541)
    ;
    Obel, Israel (58077643400)
    ;
    Okumura, Ken (56725883100)
    ;
    Olshansky, Brian (7006581028)
    ;
    Potpara, Tatjana (57216792589)
    ;
    Stiles, Martin K. (35278667100)
    ;
    Tamargo, Juan (35315133900)
    ;
    Ungar, Andrea (7006876598)
    ;
    Kosiuk, Jedrzej (55237676500)
    ;
    Larsen, Torben Bjerregaard (7202517549)
    ;
    Dinov, Borislav (13907095400)
    ;
    Estner, Heidi (6506978495)
    ;
    Garcia, Rodrigue (56411452300)
    ;
    Costa, Francisco Manuel Moscoso (57220845858)
    ;
    Lampert, Rachel (7003661257)
    ;
    Lin, Yenn-Jiang (56512618600)
    ;
    Chin, Ashley (7202019411)
    ;
    Rodriguez, Heliodoro Antonio (58253287200)
    ;
    Strandberg, Timo (56962715500)
    ;
    Grodzicki, Tomasz (16028668700)
    There is an increasing proportion of the general population surviving to old age with significant chronic disease, multimorbidity, and disability. The prevalence of pre-frail state and frailty syndrome increases exponentially with advancing age and is associated with greater morbidity, disability, hospitalization, institutionalization, mortality, and health care resource use. Frailty represents a global problem, making early identification, evaluation, and treatment to prevent the cascade of events leading from functional decline to disability and death, one of the challenges of geriatric and general medicine. Cardiac arrhythmias are common in advancing age, chronic illness, and frailty and include a broad spectrum of rhythm and conduction abnormalities. However, no systematic studies or recommendations on the management of arrhythmias are available specifically for the elderly and frail population, and the uptake of many effective antiarrhythmic therapies in these patients remains the slowest. This European Heart Rhythm Association (EHRA) consensus document focuses on the biology of frailty, common comorbidities, and methods of assessing frailty, in respect to a specific issue of arrhythmias and conduction disease, provide evidence base advice on the management of arrhythmias in patients with frailty syndrome, and identifies knowledge gaps and directions for future research. © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The interpretation of CHA2DS2-VASc score components in clinical practice: A joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA young Electrophysiologists, the association of cardiovascular nursing and Allied professionals, and the European society of cardiology council on stroke
    (2021)
    Zhang, Juqian (57196389176)
    ;
    Lenarczyk, Radoslaw (6603516741)
    ;
    Marin, Francisco (57211248449)
    ;
    Malaczynska-Rajpold, Katarzyna (35759237800)
    ;
    Kosiuk, Jedrzej (55237676500)
    ;
    Doehner, Wolfram (6701581524)
    ;
    Van Gelder, Isabelle C (7006440916)
    ;
    Lee, Geraldine (16244999000)
    ;
    Hendriks, Jeroen M (35302139800)
    ;
    Lip, Gregory Y. H (57216675273)
    ;
    Potpara, Tatjana S (57216792589)
    This European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, EHRA Young Electrophysiologists, Association of Cardiovascular Nursing and Allied Professionals, and European Society of Cardiology (ESC) Council on Stroke joint survey aimed to assess the interpretation of the CHA2DS2-VASc score components and preferred resources for calculating the score. Of 439 respondents, most were general cardiologists (46.7%) or electrophysiologists (EPs) (42.1%). The overall adherence to the ESC-defined scoring criteria was good. Most variation was observed in the interpretation of the significance of left ventricular ejection fraction and brain natriuretic peptide in the scoring for the 'C' component, as well as the 'one-off high reading of blood pressure' to score on the 'H' component. Greater confidence was expressed in scoring the 'H' component (72.3%) compared with the 'C' (46.2%) and 'V' (45.9%) components. Respondents mainly relied on their recall for the scoring of CHA2DS2-VASc score (64.2%). The three most favoured referencing resources varied among different professionals, with pharmacists and physicians relying mainly on memory or web/mobile app, whereas nurses favoured using a web/mobile app followed by memory or guidelines/protocol. In conclusion, this survey revealed overall good adherence to the correct definition of each component in scoring of the 'C', 'H', and 'V' elements of the CHA2DS2-VASc score, although the variation in their interpretations warrants further clarifications. The preferred referencing resources to calculate the score varied among different healthcare professionals. Guideline education to healthcare professionals and updated and unified online/mobile scoring tools are suggested to improve the accuracy in scoring the CHA2DS2-VASc score. © 2020 Published on behalf of the European Society of Cardiology. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Utilization and perception of same-day discharge in electrophysiological procedures and device implantations: An EHRA survey
    (2021)
    König, Sebastian (57197238602)
    ;
    Svetlosak, Martin (36926231500)
    ;
    Grabowski, Marcin (11140740100)
    ;
    Duncker, David (36090817400)
    ;
    Nagy, Vivien K. (57190756063)
    ;
    Bogdan, Stefan (56281670300)
    ;
    Vanduynhoven, Philippe (56112526600)
    ;
    Sohaib, Syed Mohammad Afzal (57224759525)
    ;
    Malaczynska-Raipold, Katarzyna (57221936454)
    ;
    Lane, Deirdre A. (57203229915)
    ;
    Lenarczyk, Radoslaw (6603516741)
    ;
    Bollmann, Andreas (7003870797)
    ;
    Hindricks, Gerhard (35431335000)
    ;
    Potpara, Tatjana S. (57216792589)
    ;
    Kosiuk, Jedrzej (55237676500)
    The aim of this European Heart Rhythm Association (EHRA) survey was to assess the utilization of same-day discharge (SDD) in electrophysiology (EP). An online-based questionnaire was shared with the EHRA community between 12 and 30 June 2020 and recorded institutional information, complication assessment, recent experiences, and opinions regarding possible advantages or concerns with SDD. In total, 218 responses from 49 countries provided information on current SDD management. Overall, SDD was implemented in 77.5%, whereas this proportion was significantly higher in tertiary and high-volume centres (83.8% and 85.3%, both P < 0.01). The concept of SDD was most commonly used following implantations of cardiac event recorders (97%), diagnostic EP procedures (72.2%), and implantations of pacemakers with one or two intracardiac leads (50%), while the lowest SDD utilization was observed after catheter ablations of left atrial or ventricular arrhythmias. Within SDD-experienced centres, ∼90% respondents stated that this discharge concept is recommendable or highly recommendable and reported that rates of increased rehospitalization and complication rates were low. Most respondents assumed a better utilization of hospital resources (78.2%), better cost effectiveness (77.3%), and an improved patients' comfort but were concerned about possible impairment of detection (72.5%) and management (78.7%) of late complications. In conclusion, >75% of respondents already implement SDD following EP interventions with a large heterogeneity with regard to specific procedures. Further research is needed to confirm or disprove existing and expected benefits and obstacles. © 2020 The Author(s).

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback